On August 30, 2019 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is reported the acceptance of abstracts for a poster presentation and an oral presentation at the 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting held November 13 through November 16, 2019 in Tokyo, Japan (Press release, Y-mAbs Therapeutics, AUG 30, 2019, View Source [SID1234539145]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstracts include the following presentations of omburtamab, one of the Company’s lead product candidates, which is currently being evaluated for the treatment of patients with CNS/Leptomeningeal metastasis from neuroblastoma, diffuse intrinsic pontine glioma ("DIPG"), and desmoplastic small round cell tumors ("DSRCT"):

· "Intraperitoneal radioimmunotherapy for desmoplastic small round cell tumor: Final results of a phase I study (clinicaltrials.gov identifier NCT01099644)," submitted by Memorial Sloan Kettering Cancer Center (MSK) in New York (poster presentation)

· "Whole abdominopelvic radiotherapy and radioimmunotherapy after complete resection of desmoplastic small round cell tumor (DSRCT): Major impact on survival," submitted by MSK in New York (oral presentation)